

# Pedro LÃ³pez-Romero

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1948169/publications.pdf>

Version: 2024-02-01

10  
papers

518  
citations

1684188

5  
h-index

1474206

9  
g-index

10  
all docs

10  
docs citations

10  
times ranked

617  
citing authors

#	ARTICLE	IF	CITATIONS
1	Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 622-631.	0.9	4
2	Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. <i>Bone</i> , 2020, 130, 115113.	2.9	7
3	Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN. <i>Arthritis Research and Therapy</i> , 2020, 22, 193.	3.5	1
4	Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial. <i>Osteoporosis International</i> , 2020, 31, 1935-1942.	3.1	12
5	Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial. <i>Calcified Tissue International</i> , 2020, 106, 646-654.	3.1	5
6	SAT0102â€¦.ASSOCIATION BETWEEN BASELINE HAEMOGLOBIN LEVELS AND RADIOGRAPHIC JOINT DAMAGE PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB OR STANDARD OF CARE. , 2019, , .		1
7	Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 783-794.	2.8	84
8	Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. <i>Lancet</i> , The, 2018, 391, 230-240.	13.7	373
9	Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study. <i>Clinical Rheumatology</i> , 2018, 37, 2381-2390.	2.2	26
10	Attention-deficit/hyperactivity disorder Under Treatment Outcomes Research (AUTOR): a European observational study in pediatric subjects. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2015, 7, 295-311.	1.7	5